Bibliografias temáticas / Hematopoietic growth factors Therapeutic use

Índice

  1. Artigos de revistas
  2. Teses / dissertações
  3. Livros
  4. Capítulos de livros
  5. Trabalhos de conferências
  6. Relatórios de organizações

Literatura científica selecionada sobre o tema "Hematopoietic growth factors Therapeutic use"

Autor: Grafiati
Publicado: 4 de junho de 2021
Última modificação: 1 de fevereiro de 2022

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Hematopoietic growth factors Therapeutic use".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "Hematopoietic growth factors Therapeutic use"

1

Costa, John J. "The therapeutic use of hematopoietic growth factors." Journal of Allergy and Clinical Immunology 101, no. 1 (January 1998): 1–6. http://dx.doi.org/10.1016/s0091-6749(98)70185-x.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Sola, Martha, and Robert D. Christensen. "Use of Hematopoietic Growth Factors in the Neonatal Intensive Care Unit." Journal of Intensive Care Medicine 12, no. 4 (July 1997): 187–205. http://dx.doi.org/10.1177/088506669701200403.

Texto completo da fonte
Resumo:
Recombinant hematopoietic growth factors have emerged as valuable treatments for a variety of medical conditions. Recently, their applications have reached the neonatal intensive care unit, where they offer new therapeutic options for problems as common as anemia of prematurity, or as catastrophic as neonatal sepsis. When facing bacterial infection, it is known that newborn infants are capable of increasing their serum G-CSF concentrations. However, their response does not reach the concentrations that adults are able to achieve, and frequently neutropenia complicates the picture of neonatal s
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Bossi, Paolo, Cristina Gurizzan, Luigi Lorini, Pierluigi di Mauro, Chiara Sardini, and Marco Merlano. "Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?" Journal for ImmunoTherapy of Cancer 9, no. 8 (August 2021): e003154. http://dx.doi.org/10.1136/jitc-2021-003154.

Texto completo da fonte
Resumo:
Myeloid growth factors, either granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF, are widely used to reduce the incidence and severity of chemotherapy-induced neutropenia by prophylactic or therapeutic administration. However, their activity in the novel therapeutic regimens, which often rely on the association between immunotherapy and chemotherapy, has not been thoroughly characterized yet. This paper presents some of the preclinical and clinical research regarding the putative interplay between myeloid growth factors and the immune system, advocating further studies
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Bridges, Sandra H., Margaret I. Johnston, and John J. McGowan. "Immunosuppression and HIV Infection: A Therapeutic Challenge." Canadian Journal of Infectious Diseases 3, suppl b (1992): 55–59. http://dx.doi.org/10.1155/1992/740587.

Texto completo da fonte
Resumo:
The optimal use of biological response modifiers (BRMs) in human immunodeficiency virus (HIV)-related disease depends on knowledge of the molecular basis of the immune deficiencies and dysregulations that occur during the course of the infection; evidence for the role of viral products and cytokines in the suppression of immune function is discussed. Immunebased therapies are currently being explored alone and in combination with drugs targeted to HIV and associated opportunistic infections and malignancies. These therapies include hematopoietic growth factors for the management of drug toxici
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Siena, Salvatore, Roberta Schiavo, Paolo Pedrazzoli, and Carmelo Carlo-Stella. "Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy." Journal of Clinical Oncology 18, no. 6 (March 13, 2000): 1360–77. http://dx.doi.org/10.1200/jco.2000.18.6.1360.

Texto completo da fonte
Resumo:
PURPOSE: To review recent advances in peripheral-blood progenitor-cell (PBPC) transplantation in order to define the optimal cell dose required for autologous and allogeneic transplantation. MATERIALS AND METHODS: A search of MEDLINE was conducted to identify relevant publications. Their bibliographies were also used to identify further articles and abstracts for critical review. RESULTS: The CD34+ cell content of a graft is regarded as an accurate predictor of engraftment success. Postchemotherapy autologous PBPC transplantation with ≥ 5 × 106 CD34+ cells/kg body weight leads to more rapid en
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Zhao, Q., X. Song, T. Waldschmidt, E. Fisher, and AM Krieg. "Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation." Blood 88, no. 5 (September 1, 1996): 1788–95. http://dx.doi.org/10.1182/blood.v88.5.1788.1788.

Texto completo da fonte
Resumo:
Abstract The use of antisense oligonucleotides as tools for modulating gene expression represents a novel strategy for designing drugs to treat a variety of diseases. Several factors, including cellular uptake and internalization of the oligonucleotides, are important parameters in determining the effectiveness of antisense agents such as therapeutic drugs. We have studied oligonucleotides uptake in normal and leukemic human hematopoietic cells, such as peripheral blood, bone marrow (BM), and HL-60 cell line; and have found that, in normal human blood and BM, myeloid cells and B cells preferab
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Zhao, Q., X. Song, T. Waldschmidt, E. Fisher, and AM Krieg. "Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation." Blood 88, no. 5 (September 1, 1996): 1788–95. http://dx.doi.org/10.1182/blood.v88.5.1788.bloodjournal8851788.

Texto completo da fonte
Resumo:
The use of antisense oligonucleotides as tools for modulating gene expression represents a novel strategy for designing drugs to treat a variety of diseases. Several factors, including cellular uptake and internalization of the oligonucleotides, are important parameters in determining the effectiveness of antisense agents such as therapeutic drugs. We have studied oligonucleotides uptake in normal and leukemic human hematopoietic cells, such as peripheral blood, bone marrow (BM), and HL-60 cell line; and have found that, in normal human blood and BM, myeloid cells and B cells preferably took u
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Thaker, Hatim, and Arun K. Sharma. "Engaging Stem Cells for Customized Tendon Regeneration." Stem Cells International 2012 (2012): 1–12. http://dx.doi.org/10.1155/2012/309187.

Texto completo da fonte
Resumo:
The need for a consistent therapeutic approach to tendon injury repair is long overdue. Patients with tendon microtears or full ruptures are eligible for a wide range of invasive and non invasive interventions, often subjectively decided by the physician. Surgery produces the best outcomes, and while studies have been conducted to optimize graft constructs and to track outcomes, the data from these studies have been inconclusive on the whole. What has been established is a clear understanding of healthy tendon architecture and the inherent process of healing. With this knowledge, tissue regene
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Mohindru, Mani, Perry Pahanish, Efstratios Katsoulidis, Robert Collins, Thomas Rogers, Tony Navas, Linda Higgins, Leonidas Platanias, and Amit Verma. "Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes." Blood 104, no. 11 (November 16, 2004): 470. http://dx.doi.org/10.1182/blood.v104.11.470.470.

Texto completo da fonte
Resumo:
Abstract Cytokines such as TNF α, IFN γ and others have been implicated in the pathogenesis of ineffective hematopoiesis in MDS and are thought to lead to the high rate of apoptosis in hematopoietic progenitors. The p38 Mitogen Activated Protein Kinase (MAPK) is an evolutionary conserved enzyme that is involved in many cellular processes including stress signaling. We have previously shown that the p38 MAP kinase is strongly activated by IFNs, TNF α, TGF β and other inhibitory cytokines in normal primary hematopoietic progenitors and plays an important role in the negative regulation of normal
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Or, Reuven, Sigal Grisaro, Batia Ronit Avni, Igor Resnick, Lilyan Dari, David Shoshani, Dalia Bracha, Nurit Beilin, Limor Lior, and Michael Y. Shapira. "Correction of Post-Transplant Hematopoiesis by Novel Use of Mesenchymal-Like Placental Expanded Cells (PLX) Administered Intra-Muscular." Blood 120, no. 21 (November 16, 2012): 4133. http://dx.doi.org/10.1182/blood.v120.21.4133.4133.

Texto completo da fonte
Resumo:
Abstract Abstract 4133 Post autologous or allogeneic stem cell transplantation hematopoietic dysfunction is a common phenomenon caused by multiple factors. Complicating the treatment of this condition is the fact that additional reserves of stem cells for autologous transplantation is usually unavailable and the use of allogeneic stem cells, if available, may be associated with transplant related complications, including graft versus host disease. Furthermore, the addition of donor cells may be ineffective because the underlying disease may also damage the supplemented stem cells. Prolonged pa
Estilos ABNT, Harvard, Vancouver, APA, etc.
Mais fontes

Teses / dissertações sobre o assunto "Hematopoietic growth factors Therapeutic use"

1

Ang, Main-fong, and 洪明楓. "Ex vivo expansion of hematopoietic stem cells: preclinical studies and clinical application." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B3122815X.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Haylock, David Norman. "Ex vivo expansion of human haemopoietic progenitor cells." Title page, abstract and contents only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phh4181.pdf.

Texto completo da fonte
Resumo:
"December 2001." Includes bibliographical references (leaves 178-225) Focuses on the ex vivo growth of human haemopoietic progenitor cells with the objective of defining culture conditions for generating myeloid post-progenitor cells for therapy
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Hercus, Timothy Robert. "Structure-junction studies on human granulocyte-macrophage colony-stimulating factor /." Title page, table of contents and summary only, 1994. http://web4.library.adelaide.edu.au/theses/09PH/09phh539.pdf.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Korpelainen, Eija. "Interleukin -3 receptor expression and function in now-hemopoietic cells /." Title page, contents and abstract only, 1995. http://web4.library.adelaide.edu.au/theses/09PH/09phk84.pdf.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Ng, Hoi-man, and 伍凱敏. "Regulation of vascular endothelial growth factor by ginsenoside RG1 inhuman endothelial cells." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43955915.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

"The effects of hematopoietic growth factors and tanshinone IIA on neuro-protection." Thesis, 2005. http://library.cuhk.edu.hk/record=b6073980.

Texto completo da fonte
Resumo:
Neonatal hypoxic-ischemic encephalopathy (HIE) is a common clinical problem. Tanshinone IIA is a compound purified from the Chinese herb Danshen ( Radix Salviae Miltiorrhiza Bge). Thrombopoietin (TPO) and Erythropoietin (Epo) are hematopoietic growth factors. The effects of tanshinone IIA, EPO and TPO on hypoxia-ischemia brain injury were investigated in this study, using in vitro model of neural cell culture and an in vivo model of hypoxic-ischemic brain damage.<br>Our observation provided the first evidence showing the expression of functional TPO receptor c-mpl in central nervous system. It
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Hunt, Benjamin Matthew. "Recovery of transforming growth factor-[beta]2 from Whey Growth Factor Extract with immunoaffinity techniques / by Benjamin Matthew Hunt." 2000. http://hdl.handle.net/2440/19851.

Texto completo da fonte
Resumo:
Includes errata on last 3 leaves.<br>Includes bibliographical references (leaves 232-246).<br>xix, 246 leaves : ill. (some col.) ; 30 cm.<br>Title page, contents and abstract only. The complete thesis in print form is available from the University Library.<br>Describes attempts to develop an immunoaffinity process for commercial-scale purification of TGF-[beta]2 from Whey Growth Factor Extract<br>Thesis (Ph.D.)--Adelaide University, Dept. of Chemical Engineering, 2001
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Sekhejane, Palesa Rose. "Effect of low level laser irradiation on expression of cytokines and growth factors involved in wound healing." Thesis, 2010. http://hdl.handle.net/10210/3121.

Texto completo da fonte
Resumo:
M. Tech.<br>Phototobiomodulation (PBM), also known as low level laser therapy (LLLT) or photobiostimulation, is a non-invasive form of therapy that utilizes low intensity laser light or irradiation to provide healing. However, in order for healing to be successful certain laser parameters need to be taken into consideration i.e. fluence (dosage), wavelength and power density. Laser therapy has been used for various medical applications and fields. Multiple cytokines and growth factors are involved in wound healing including Interleukin (IL)-1, IL-6 and Tumour Necrosis Factor alpha (TNF- a). In
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Martin, Holly René. "Mechanism of Transformation and Therapeutic Targets for Hematological Neoplasms Harboring Oncogenic KIT Mutation." Thesis, 2014. http://hdl.handle.net/1805/5503.

Texto completo da fonte
Resumo:
Indiana University-Purdue University Indianapolis (IUPUI)<br>Gain-of-function mutations in the KIT receptor tyrosine kinase have been associated with highly malignant human neoplasms. In particular, an acquired somatic mutation at codon 816 in the second catalytic domain of KIT involving an aspartic acid to valine substitution is found in patients with systemic mastocytosis (SM) and acute myeloid leukemia (AML). The presence of this mutation in SM and AML is associated with poor prognosis and overall survival. This mutation changes the conformation of the KIT receptor resulting in altered subs
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Rodrigues, Maria Inês Moreira Patrício. "New roles of Rab GTPases on eye diseases: targeting VEGF secretion." Doctoral thesis, 2012. http://hdl.handle.net/10362/10533.

Texto completo da fonte
Resumo:
RESUMO: A retina é composta, entre outras estruturas, pelo epitélio pigmentar da retina (EPR)e pela coróide. A região central da retina denomina-se mácula, e é a zona mais afetada na degenerescência macular relacionada com a idade, a forma mais comum de degenerescência da retina. Nesta doença, a secreção de fatores de crescimento pelo EPR é afetada, nomeadamente a do fator de crescimento vascular endotelial (VEGF), e pouco se sabe ainda sobre os mecanismos moleculares conducentes a esta condição. A família de proteínas Rab GTPases está envolvida nas vias intracelulares de sinalização e tráfego
Estilos ABNT, Harvard, Vancouver, APA, etc.

Livros sobre o assunto "Hematopoietic growth factors Therapeutic use"

1

C, Dale David, and SpringerLink (Online service), eds. Hematopoietic Growth Factors in Oncology. Boston, MA: Springer Science+Business Media, LLC, 2011.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

L, Spivak Jerry, Drohan William, and Dooley Douglas, eds. Hematopoietic growth factors in transfusion medicine: Proceedings of the XXth Annual Scientific Symposium of the American Red Cross, held in Bethesda, Maryland, May 10-11, 1989. New York: Wiley-Liss, 1990.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

J, Quesenberry Peter, Asano Shigetaka 1943-, and Saito Kazuhisa 1922-, eds. Hematopoietic growth factors: Molecular biology to clinical applications of rG-CSF : proceedings of a satellite symposium of the Sixth International Congress of Mucosal Immunology, Tokyo, July 22, 1990. Amsterdam: Excerpta Medica, 1991.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Th, Smit Sibinga C., Das P. C, and Fratantoni Joseph C, eds. Alternative approaches to human blood resources in clinical practice: Proceedings of the Twenty-Second International Symposium on Blood Transfusion, Groningen 1997. Dordrecht: Kluwer Academic, 1998.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Dworkin, Chaim R. The use of growth factors in cancer therapy. [Bethesda, Md.?]: U.S. DHHS, PHS, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1993.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Van de Water, Thomas R. and Koszer Samuel, eds. Clinical applications of neurotrophic factors. Philadelphia: Lippincott-Raven, 1997.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Krul, Kenneth G. Emerging cancer therapies. Waltham, MA: Decision Resources, 1994.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Sherbet, G. V. Growth factors and their receptors in cell differentiation, cancer and cancer therapy. London: Elsevier, 2011.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Bengt, Westermark, Betsholtz Christer, and Hökfelt Bernt, eds. Growth factors in health and disease: Basic and clinical aspects : proceedings of the 4th Nordisk Insulin Symposium "Growth Factors in Health and Disease," Copenhagen, Denmark, 18-20 June 1990. Amsterdam: New York :Excerpta Medica, 1990.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Anti-VEGF. Basel: Karger, 2010.

Encontre o texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Mais fontes

Capítulos de livros sobre o assunto "Hematopoietic growth factors Therapeutic use"

1

Nimer, Stephen D., and Richard E. Champlin. "Therapeutic use of hematopoietic growth factors in bone marrow transplantation." In Cancer Treatment and Research, 141–64. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-1493-6_9.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Seipelt, G. "Clinical Use of Hematopoietic Growth Factors." In Antibiotics and Chemotherapy, 94–105. Basel: KARGER, 1999. http://dx.doi.org/10.1159/000059319.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Mininberg, Eric D., and Frankie Ann Holmes. "Use of Granulocyte Growth Factors in Breast Cancer." In Hematopoietic Growth Factors in Oncology, 285–309. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-747-5_15.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Foote, MaryAnn. "Use of Hematopoietic Growth Factors in AIDS-Related Malignancies." In Hematopoietic Growth Factors in Oncology, 357–71. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-747-5_18.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Lichtin, Alan E. "Clinical Practice Guidelines for the Use of Erythroid-Stimulating Agents: ASCO, EORTC, NCCN." In Hematopoietic Growth Factors in Oncology, 239–48. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-7073-2_14.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
6

Finke, Jürgen, and Roland Mertelsmann. "Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation." In Thomas’ Hematopoietic Cell Transplantation, 480–91. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118416426.ch43.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
7

Fox, Richard M. "Commentary on the ASCO and ESMO Evidence-Based Clinical Practice Guidelines for the Use of Hematopoietic Colony-Stimulating Factors." In Hematopoietic Growth Factors in Oncology, 211–17. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-747-5_10.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
8

Demetri, George D. "Evidence-Based Use of Hematopoietic Cytokines in Clinical Oncology." In Clinical Applications of Cytokines and Growth Factors, 137–49. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-5013-6_6.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
9

Jendiroba, David B., Benjamin Lichtiger, and Emil J. Freireich. "The Use of Hematopoietic Growth Factors for Recruitment of Leukocytes for Transfusion." In Clinical Applications of Cytokines and Growth Factors, 178–85. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-5013-6_9.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
10

Vose, J. M., E. C. Reed, P. J. Bierman, and J. O. Armitage. "Autologous Bone Marrow Transplantation for Lymphoid Malignancies: The Use of Hematopoietic Growth Factors." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 201–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78350-0_34.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.

Trabalhos de conferências sobre o assunto "Hematopoietic growth factors Therapeutic use"

1

Barminko, Jeffrey, Jean Pierre Dolle, Rene Schloss, Martin Grumet, and Martin L. Yarmush. "Encapsulated Mesenchymal Stem Cells for Central Nervous System Repair." In ASME 2010 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2010. http://dx.doi.org/10.1115/sbc2010-19712.

Texto completo da fonte
Resumo:
Mesenchymal stromal cells (MSC) have long been regarded as a cell source with the potential to provide therapies for various different tissue pathologies. They were originally identified for their ability to adhere to tissue culture plastic and gained favor due to their tremendous ability to propagate[1]. It was this finding as well as their ability to differentiate into lineages of mesoderm which have long made MSC a potential tool for autologous cellular replacement therapies [2, 3]. More recently, their cyto-protective role has been realized and been implicated in the benefit achieved in tr
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Nagy, Diána. "Possibilities of Digitalization and Service Design in the Development of Patient Adherence." In New Horizons in Business and Management Studies. Conference Proceedings. Corvinus University of Budapest, 2021. http://dx.doi.org/10.14267/978-963-503-867-1_05.

Texto completo da fonte
Resumo:
In parallel with the development of modern health systems and the growth of the welfare state, diseases have shifted towards chronic diseases. Today, instead of rapid-onset infections, most resources are focused on the long-term treatment of mostly lifelong chronic conditions. The condition for the effective use of therapies is to take the specified dose with the prescribed frequency and for the required period of time. If these parameters are met, we can talk about patient collaboration or adherence. For certain diseases and treatments, adherence is critically low. In the case of complex prep
Estilos ABNT, Harvard, Vancouver, APA, etc.
3

Devi, Pinki, Ganapathi Bhat, and Harish S. Ahuja. "To Predict Success of Postapheresis Yield and Post–Autologous Transplant Engraftment Based on Preapheresis Peripheral Blood CD34+ Cell Counts: An Indian Scenario–Based Study." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735370.

Texto completo da fonte
Resumo:
Abstract Introduction The use of hematopoietic stem cells for autologous and allogeneic transplantation has increased in the recent past significantly, due to introduction of newer chemotherapeutic drugs, immunological techniques, and better stem cell technology. Among the bone marrow and peripheral blood stem cells, collection of the latter being more convenient to the patient and associated with faster granulocyte and platelet engraftment has been known as preferred method for mobilization. Peripheral blood stem cells can be extracted from the autologous or allogeneic donor. Mobilization of
Estilos ABNT, Harvard, Vancouver, APA, etc.
4

Arora, Rahul D. "Definition, etiopathogenesis, management and role of flouroquinolone prophylaxis in prevention of spontaneous bacterial peritonitis complicating malignant ascites." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685345.

Texto completo da fonte
Resumo:
Background: Malignancy related ascites encompasses multiple etiologies which include peritoneal carcinomatosis, hepatic synthetic dysfunction due to parenchymal involvement by the tumour, transcoeloemic metastasis and chylous ascites due to lymphatic obstruction. Primary Cancer type, liver metastasis and serum albumin have been listed as independent prognostic markers in malignant ascites. Spontaneous Bacterial Peritonitis is usually seen as a complication of decompensated chronic liver disease due to translocation of bacteria or haematogenous dissemination from a distant focus of infection. T
Estilos ABNT, Harvard, Vancouver, APA, etc.
5

Yuan, Yuan, and Diana-Andra Borca-Tasciuc. "The Influence of Coating and Agglomeration on Specific Absorption Rate of Iron Oxide Nanoparticles." In ASME 2011 9th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2011. http://dx.doi.org/10.1115/icnmm2011-58217.

Texto completo da fonte
Resumo:
Magnetic nanofluids can be remotely heated by alternating magnetic field and have significant potential for cancer hyperthermia therapy. The heat generated by magnetic nanoparticles is typically quantified by the specific absorption rate (SAR), which represents the thermal power per unit mass of magnetic material generated in the presence of an alternating magnetic field. During hyperthermia treatment, heat dosage of tumor tissue correlates with slowing tumor growth. The therapeutic ratios of cancer can be increased with the use of biofunctionalized magnetic nanoparticles that have higher SAR
Estilos ABNT, Harvard, Vancouver, APA, etc.

Relatórios de organizações sobre o assunto "Hematopoietic growth factors Therapeutic use"

1

Sytkowski, Arthur J. Development of Hematopoietic Growth Factors for Use in Military Personnel. Fort Belvoir, VA: Defense Technical Information Center, July 1991. http://dx.doi.org/10.21236/ada242475.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
2

Sytkowski, Arthur J. Development of Hematopoietic Growth Factors for Use in Military Personnel. Fort Belvoir, VA: Defense Technical Information Center, August 1990. http://dx.doi.org/10.21236/ada238603.

Texto completo da fonte
Estilos ABNT, Harvard, Vancouver, APA, etc.
Você também pode estar interessado nas extensas listas de trabalhos sobre o assunto "Hematopoietic growth factors Therapeutic use":
Artigos de revistas Livros
Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!

Vá para a bibliografia